biote (BTMD) Scheduled to Post Earnings on Tuesday

biote (NASDAQ:BTMD) is scheduled to announce its earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of $0.09 per share for the quarter. biote has set its FY 2024 guidance at EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

biote (NASDAQ:BTMD) last posted its earnings results on Thursday, August 8th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.05. biote had a net margin of 3.67% and a negative return on equity of 20.92%. The company had revenue of $49.17 million during the quarter, compared to analysts’ expectations of $50.40 million. On average, analysts expect biote to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

biote Stock Performance

Shares of BTMD traded up $0.08 during midday trading on Tuesday, hitting $5.25. 19,861 shares of the company traded hands, compared to its average volume of 161,384. biote has a 52 week low of $3.65 and a 52 week high of $8.44. The firm has a 50 day moving average of $5.59 and a 200-day moving average of $6.27. The stock has a market cap of $284.66 million, a price-to-earnings ratio of 30.41 and a beta of 0.94.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.